• Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer. 

  Mukherjee, UA; Hockings, H; Counsell, N; Patel, A; Narayanan, P; Wilkinson, K; Dhanda, H; Robinson, K; McNeish, I; Anderson, ARA (BMJ Publishing Group, 2024-12-22)

  INTRODUCTION: Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relapsed, platinum-sensitive ...

• Author Correction: Disentangling oncogenic amplicons in esophageal adenocarcinoma. 

  Ng, AWT; McClurg, DP; Wesley, B; Zamani, SA; Black, E; Miremadi, A; Giger, O; Hoopen, RT; Devonshire, G; Redmond, AM (Springer Nature, 2024-05-28)

• Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study 

  Graham, R; MacDonald, ND; Lockley, M; Miller, R; Butler, J; Murali, K; Sarker, S-J; Banerjee, S; Stoneham, S; Shamash, J (Elsevier, 2022-02-16)

• Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference 

  Pashankar, F; Hanley, K; Lockley, M; Stoneham, S; Nucci, MR; Reyes-Mugica, M; Elishaev, E; Vang, R; Veneris, J; Rytting, H (Elsevier, 2022-07-18)

• The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma 

  Smith, P; Bradley, T; Gavarro, LM; Goranova, T; Ennis, DP; Mirza, HB; De Silva, D; Piskorz, AM; Sauer, CM; Al-Khalidi, S (Springer Nature, 2023-07-20)

• Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention. 

  Nuttall Musson, E; Miller, RE; Mansour, MR; Lockley, M; Ledermann, JA; Payne, EM (Springer Nature, 2024-11-17)

• Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship. 

  Travis, LB; Feldman, DR; Fung, C; Poynter, JN; Lockley, M; Frazier, AL (American Society of Clinical Oncology (ASCO), 2023-10-11)

  Innovations in the care of adolescent and young adult (AYA) germ cell tumors (GCTs) are needed for one of the most common AYA cancers for which treatment has not significantly changed for several decades. Testicular GCTs ...

• Identification, Monitoring and Reversibility of PARP Inhibitor Associated Clonal Haematopoiesis and Myelodysplastic Syndrome: A Case Series 

  Musson, EN; Lockley, M; Mansour, MR; Miller, RE; Lederman, J; Payne, E (American Society of Hematology, 2023-11-02)

• Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London. 

  El-Shakankery, KH; Kefas, J; Palmer, K; Houston, A; Mukherjee, U; Gao, K; Tan, W; Crusz, SM; Flynn, MJ; Ledermann, JA (MDPI, 2024-10-24)

  BACKGROUND: Ethnic and socioeconomic disparities in cancer outcomes are exacerbated by clinical trial underrepresentation. This study aims to identify inequalities in ethnicity and socioeconomic features among ovarian ...

• Comparison of overall and patterns of care in patients with a malignant ovarian germ cell tumor by age in the United States: a National Cancer Database (2004-2016) analysis. 

  Sullivan, SM; Stoneham, S; Lockley, M; Frazier, AL; Billmire, DF; Poynter, JN (Elsevier, 2025-01-03)

  BACKGROUND: Women aged ≥40 years diagnosed with a malignant ovarian germ cell tumor are more likely to have poor outcomes than their younger counterparts (aged 15-39 years). OBJECTIVE: We used the National Cancer Database ...

• Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild-type <i>TP53</i> and mutant <i>KRAS, G3BP1</i> and <i>IL7R</i> 

  Goldgraben, MA; Fewings, E; Larionov, A; Scarth, J; Redman, J; Telford, N; Arkwright, PD; Bonney, D; Wilks, D; Kulkarni, S (2020)

• Germline pathogenic variants in <i>PALB2</i> and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without <i>CDH1</i> mutation: a whole-exome sequencing study 

  Fewings, E; Larionov, A; Redman, J; Goldgraben, MA; Scarth, J; Richardson, S; Brewer, C; Davidson, R; Ellis, I; Evans, DG (2018)

• E6-mediated activation of JNK drives EGFR signalling to promote proliferation and viral oncoprotein expression in cervical cancer 

  Morgan, EL; Scarth, JA; Patterson, MR; Wasson, CW; Hemingway, GC; Barba-Moreno, D; Macdonald, A (2021)

• Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families 

  Yang, X; Leslie, G; Doroszuk, A; Schneider, S; Allen, J; Decker, B; Dunning, AM; Redman, J; Scarth, J; Plaskocinska, I (2020)

• Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma 

  Abdel-Rahman, MH; Sample, KM; Pilarski, R; Walsh, T; Grosel, T; Kinnamon, D; Boru, G; Massengill, JB; Schoenfeld, L; Kelly, B (2020)

• CREB1 activation promotes human papillomavirus oncogene expression and cervical cancer cell transformation. 

  Li, Y; Patterson, MR; Morgan, EL; Wasson, CW; Ryder, EL; Barba-Moreno, D; Scarth, JA; Wang, M; Macdonald, A (2023-08)

  Human papillomaviruses (HPVs) infect the oral and anogenital mucosa and can cause cancer. The high-risk (HR)-HPV oncoproteins, E6 and E7, hijack cellular factors to promote cell proliferation, delay differentiation and ...

• The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer 

  Morgan, EL; Patterson, MR; Barba-Moreno, D; Scarth, JA; Wilson, A; Macdonald, A (2021)

• A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer 

  Acha-Sagredo, A; Andrei, P; Clayton, K; Taggart, E; Antoniotti, C; Woodman, C; Afrache, H; Fourny, C; Armero, M; Kaja Moinudeen, H (Cell Press, 2025-01-16)

  Highlights • CRCs can be grouped into IFN-high or low immunophenotype based on 7 gene signatures • CRC patients responding to immunotherapy have IFN-high immunophenotype • IFN-high CRCs show high T cell-induced ...

• Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice. 

  Njegić, A; Laid, L; Zi, M; Maniati, E; Wang, J; Chelu, A; Wisniewski, L; Hunter, J; Prehar, S; Stafford, N (Elsevier Ltd., 2024-06)

  Heart failure remains one of the largest clinical burdens globally, with little to no improvement in the development of disease-eradicating therapeutics. Integrin targeting has been used in the treatment of ocular disease ...

• Homopolymer switches mediate adaptive mutability in mismatch repair-deficient colorectal cancer. 

  Kayhanian, H; Cross, W; van der Horst, SEM; Barmpoutis, P; Lakatos, E; Caravagna, G; Zapata, L; Van Hoeck, A; Middelkamp, S; Litchfield, K (Springer Nature, 2024-07-03)

  Mismatch repair (MMR)-deficient cancer evolves through the stepwise erosion of coding homopolymers in target genes. Curiously, the MMR genes MutS homolog 6 (MSH6) and MutS homolog 3 (MSH3) also contain coding homopolymers, ...

View more